AOP Health opens its Italian base in Pisa
The Austrian company, a pioneer in solutions and treatments for rare diseases and critical care, has inaugurated its office in Pisa and presented the plans for Italy.
Pisa, 20th May 2022. AOP Health, the Austrian pharmaceutical company, a pioneer in Europe for integrated therapies for rare diseases and critical care, chose Pisa as its base for Italian operations and inaugurated its new offices yesterday. From here, the company will coordinate all the activities nationwide.
“AOP Health has 25 years of experience in developing innovative, disease management solutions and making them available long-term: We invest around 20% of our revenue in research and development every year. This way we are making sure to reach patients who suffer from rare diseases or who are in a critical care status. From now on we will be able to reach Italian patients even better, as Italy has become one of our most important markets in Europe”, says Georg Fischer, AOP Health CEO of the Group’s headquarters in Vienna, Austria.
Present in Italy since 2019, AOP Health is at the service of patients suffering from rare diseases and needing critical care – and of the healthcare professionals taking care of them – with innovative therapeutic solutions in three therapeutic areas: Hemato-Oncology, Cardiology & Pulmonology and Critical Care. “Since the beginning of the year, we started an important growth phase and we chose Pisa as our operational base for the development we have in plan for Italy” said Nicola Zancan, AOP Health General Manager in Italy. “We are bringing to the Italian market new integrated therapies potentially able to make a significant difference in the treatment of people suffering from Polycythemia Vera, a rare and chronic blood cancer, and from Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension, lung diseases that – if not properly treated – cause a dangerous heart failure. We are very proud to offer solutions that will change the lives of patients and their families and to offer professionals additional treatment options”.
AOP Health, focused on the research and development of drugs and integrated solutions for rare diseases and intensive care since 25 years, has established its Italian base in Pisa, a hub considered particularly attractive for its location and logistics, for the presence of prestigious universities that make it an unquestioned city of science, but also for the research activities and the vitality of the start-ups in biotech and nanotechnologies that make this area particularly fertile for the scientific and research work of AOP Health. The establishment of the company, with its activities, in the area will activate further innovation and development, increasing opportunities in the field of “science of the care of health”.
The Group, overall, expects to reach 1 billion in turnover in 2030 worldwide and in such growth context Italy, considered a key strategic country, will play a primary role. In order to reach such goals, several investment projects in Italy are under evaluation and also a growth in human resources. The company aims to include people with a strong sense of ethics and responsibility, in addition to the necessary professional skills, given the exceptionally sensitive area we operate in.
In Italy, AOP Health collaborates daily with leading Universities and the scientific world, both for the implementation of clinical studies related to the development of new drugs and for the collection of clinical data following the launch of new molecules – the so called “real life studies” which assess the data deriving from clinical practice, and which are used for the constant improvement of therapies. Precisely in collaboration with Azienda Ospedaliera Pisana an international clinical study has recently been completed, with the objective of investigating efficacy and safety of a drug used in emergency care. AOP Health also collaborates with entities like Fondazione FROM – Fondazione per la Ricerca dell’Ospedale di Bergamo – with Policlinico Universitario Gemelli and Scientific Societies like SIAARTI – Società Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva.
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as the doctors and healthcare professionals treating them.
Sartori Comunicazione & PR
Claudia Sartori | mob. 334.3936863 | email@example.com
Denise Dreon | mob. 333.9049223 | firstname.lastname@example.org
AOP Health | email@example.com